Azymetric platform

Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
Pharmaceutical Business Review
Mon, 01/21/19 - 10:49 am
Eli Lilly
Zymeworks
drug development
Azymetric platform